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Venous Thromboembolism in Trauma Patients
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important health care problem resulting in significant morbidity, mortality, and health care expenditures. Clinicians attribute VTE to the abnormalities described as Virchow's triad: venous stasis, intimal injury, and a hypercoagulable state. All three conditions commonly occur in trauma patients.
Hospitalized patients recovering from major trauma are among those at highest risk of developing VTE. In fact, PE is the third most frequent cause of in-hospital death in trauma patients who survive more than 24 hours after injury. 1 The reported incidence of VTE in trauma patients varies between studies, presumably as a result of heterogeneity in the risk profile such as the nature of their injuries, the method of diagnosis, and whether routine surveillance was performed. If VTE prophylaxis is not used, the incidence of DVT may exceed 50%, with half of patients demonstrating no symptoms. was counterbalanced by a significant increase in DVT (IVCF group 36% vs. no filter group 28%; p = .042) with no effect on long-term mortality. 4, 5 These data indicate that filters, when used in conjunction with anticoagulation, offer a short-term reduction in the total number of PEs at the cost of a long-term increase in recurrent DVT with no reduction in mortality. Unfortunately, because 94% of patients received anticoagulation for at least 3 months, these data offer no insight into the outcome of the typical patient who has had a vena caval filter due to a contraindication to anticoagulant therapy.
Since the FDA approval of the Gunther Tulip™ Vena Cava Filter for retrieval in 2003, six new retrievable filters have been approved for use in the United States and filter use has increased dramatically. 6 In 2003, the FDA approved changes to three existing permanent filters to allow percutaneous retrieval, but did not specify retrieval indications. 7 The rationale for using retrievable IVCFs is to offer mechanical protection against PE during the limited high-risk period when anticoagulation may be contraindicated. The largest proportional increase in the use of retrievable IVCFs in the United States has been in patients at risk for PE but who have neither PE nor DVT (i.e.
prophylactic IVCFs). 2 Overall, IVCF insertion has increased significantly during the past 10 years in trauma patients. 8, 9 Over the last decade IVCF placement increased by 111% in the Medicare population. 10 Data from the National Hospital Discharge Survey indicate that 49,000 hospitalized patients received an IVCF in 1999. 6 Based on the most recent data from this registry, 92,000 patients received IVCFs in 2006, representing an almost 200% increase. 6 In 2012, vena cava filter sales are expected to exceed 250,000
units of which 80% (200,000) are expected to be retrievable filters. 11 The considerable variation in use of IVCFs cannot be explained by patient or center characteristics. 12 Acute complications of filter placement include improper positioning, tilting, and insertion site thrombosis. Long term complications are DVT, inferior vena cava (IVC) obstruction, filter migration, strut fracture, filter erosion through the IVC, and proximal PE. Timely removal may prevent most of these complications, which provides the rationale for the increasing popularity for retrievable filters. More than half of IVCFs are placed for temporary prophylaxis and therefore should be removed. [13] [14] [15] [16] However, retrospective studies report that the rate of removal of these retrievable filters is only approximately 20%. [17] [18] [19] [20] The overall retrieval rate is a product of the clinical and procedural rate. 21 If attempted, ~ 90% of IVCF retrievals are successful. 21 Procedural factors associated with retrieval failure include prolonged dwelling time, advanced age, filter head position, and filter design. [22] [23] [24] The true time frame for successful retrieval of IVCFs remains undefined, but proceduralists have reported retrieval as long as 494 days after insertion. 25 Clinical factors that influence whether or not IVCF retrieval is attempted include comorbidities, concurrent anticoagulation, primary indication for placement, and documented plans for removal at the time of insertion or when the patient is discharged. 19, 26 On August 8, 2010 the FDA issued a safety alert encouraging timely removal of IVCFs in order to avoid long-term complications. 27 Therefore, improving the rate of IVCF retrieval is an important objective and strategies to increase retrieval rates are needed.
Pilot Feasibility Study
Despite conflicting data on their efficacy, pIVCFs have become part of the treatment algorithm at many trauma centers for prevention of VTE in trauma patients at highest risk. However, the use of pIVCF in any patient population remains controversial. . 29 This dichotomy in clinical recommendations may reflect differences in practice patterns across trauma centers in North America. Therefore we designed this pilot study to determine the feasibility of performing a prospective randomized controlled trial of pIVCF use among high-risk trauma patients.
The goal of a pilot feasibility study is to identify issues related to study conceptualization, design, sample size and patient selection, data collection procedures, and approaches for data analysis. 30 This type of clinical investigation is essential for maximizing the success of a future prospective trial. Pilot studies with explicit feasibility objectives and a priori success criteria are important foundation steps to prepare for a large trial, ensuring a rigorous trial design that is implemented efficiently and safely. 31 The Filters in Trauma (FIT) Pilot Study was designed to optimally prepare for a larger multicenter randomized controlled trial evaluating the efficacy and safety of pIVCFs in trauma patients. Herein the outcomes of this pilot feasibility study are
represented. In addition, the logistics of the trial design and implementation barriers that were identified over the first two years that the study was open for enrollment are delineated.
Study Objectives
The primary outcome measures of this pilot study were the following feasibility objectives: 1) timely enrollment of high-risk trauma patients, 2) acceptable time to randomization, 3) timely receipt of allocated treatment, 4) adherence to weekly lowerextremity surveillance compression ultrasounds (CUS). Secondary objectives were to obtain preliminary data on VTE event rates at hospital discharge, 1 month, and 6 months post-discharge. Additionally, barriers to recruitment and randomization, use of pharmacologic prophylaxis, prescription of sequential compression devices (SCDs), compliance with follow-up, and removal rates of filters were examined. METHODS
Patient Population
This was a single institution prospective randomized pilot study to evaluate the feasibility of investigating the use of pIVCFs in HRTPs at the University of Florida in Gainesville, Florida. The study opened for enrollment in November 2008. All patients were recruited from Shands Hospital at the University of Florida, a Level 1 trauma center serving 13 counties in North Central Florida with a population base of 1.1 million citizens. Prior to this study the standard of practice at the University of Florida for VTE primary prophylaxis included placement of pIVCF in any trauma patient deemed highrisk for VTE. In addition, immediate pharmacologic prophylaxis was used when deemed safe by the primary service, usually within 24 hours.
The inclusion criteria for this study were based on the EAST guidelines for highrisk trauma patients. 28 Patients considered high-risk for VTE and therefore included in the study were those over the age 18 admitted to the trauma service within 96 hours before the enrollment, and with at least one of the following injury patterns: 1) spinal cord injury with paralysis; 2) multiple complex pelvic fractures; 3) bilateral lowerextremity (LE) long bone fractures, excluding fibula; 4) pelvic fracture plus one or more LE long bone fracture(s) excluding fibula; 5) expected non-weight bearing bilaterally > 7 days; 6) body mass index (BMI) > 35kg/m 2 . All patients were required to have expected hospitalization for > 1 week to ensure at least two CUS of the LE were performed prior to hospital discharge. In addition, to be eligible, patients must have had a negative baseline lower-extremity CUS. Patients were excluded if they had indications for therapeutic anticoagulation, had a previous IVCF or contraindications for IVCF placement, or were deemed to be ineligible for pharmacologic prophylaxis throughout their entire hospital stay. Additional exclusion criteria included inability to obtain informed consent from the patient or proxy; pregnant, institutionalized, or terminally ill patients; or anticipated survival < 24hours.
The University of Florida Institutional Review Board (IRB) approved this study.
An independent data safety monitoring board (DSMB) comprising a hematologist, a cardiologist, and a vascular surgeon at our institution was convened every four months to investigate potential adverse events and safety issues. Pre-specified stopping rules included a 10% absolute difference of fatal PEs or deaths between the two treatment groups. This absolute difference was chosen based on heterogeneous population studies in which a total event rate of fatal PEs or death were reported to be less than 10%.
Study Design
Physicians on the admitting trauma service were the first points of contact to introduce the study to eligible patients. After immediate stabilization and initial surgical procedures, the principal investigator or study coordinator, who were not affiliated with the direct care of the patient, obtained written informed consent from the patient or legally authorized representative. Once enrolled in the study, patients underwent computer-generated simple randomization to receive pIVCF placement or no pIVCF. 
Study Outcomes
The primary outcomes were the feasibility objectives described above. A priori we specified the following criteria to define success of this pilot feasibility study: 1) timely enrollment within 96 hours of admission, 2) randomization within 24 hours of enrollment, 3) treatment allocation within 48 hours of randomization, and 4) adherence with weekly surveillance CUS during hospitalized. Secondary outcome measures included: 1) event rates of PE, DVT, and death; 2) investigation of barriers to recruitment and randomization; 3) pharmacologic prophylaxis initiation; 4) compliance with follow-up; 5) filter retrieval rates.
Statistical Analysis
The goal of this feasibility study was to inform the planning of a large multicenter randomized controlled clinical trial (RCCT). By design, the FIT Pilot Study was not powered to determine the relative benefit of pIVCF versus no pIVCF on the development of PE. A sample size of convenience was chosen based on hospital record review, which indicated that approximately 200 patients per year received a pIVCF prior to initiation of the FIT Pilot Study. A sample size of 100 patients was targeted over a 12-month enrollment phase. It was felt that this sample size would be sufficient to address issues related to the consent process, to refine the protocol as needed, identify barriers to conduction of the study, and perform an interim analysis.
Statistical analysis was performed with SAS (version 9.2; SAS Inc., Cary, NC). of 38 were eligible for analysis (Figure 3-1) . Differences between socio-demographic and clinical characteristics in the IVCF group and non-IVCF group were not significantly different (Table 3 -1). The DSMB met every 4 months and all DSMB reports were conveyed to the IRB. There were no acute complications related to the device placement and no serious adverse events that required stopping the study by the oversight of the DSMB.
Primary Outcomes
Results of the primary feasibility objectives (Table 3- refusal of consent (n=23), inability to obtain informed consent and no next of kin identified (n=12), research staff or translator unavailable to obtain informed consent (n=6), delayed notification by primary service of eligible patient (n=2), patient received pIVCF prior to notification of eligibility (n=5), site unable to place IVCF (n=4), patient unavailable for consent (n=1). There were no barriers to randomization once informed consent was obtained.
Secondary Outcomes
At 6-month follow-up, one PE was diagnosed in the non-IVCF group, one death unrelated to VTE in the IVCF group, and no DVT in either group (Table 3- In the IVCF group, we were able to reach 80% of patients for 1-month follow-up compared with 100% in the non-IVCF group (p=0.07). At 6 months post-discharge, follow-up dropped off in each group (40% in IVCF and 60% in non-IVCF, p=0.28) ( Table   3- to follow-up and 20% were deemed to be at continued risk for VTE. Fifty-three eligible patients were not enrolled. Barriers to enrolling these patients included mainly patient refusal to participate or no next of kin identified for informed consent, a common dilemma in trauma studies. 34 Other barriers to recruitment were delayed notification by the primary service of an eligible patient and inability to obtain timely informed consent due to logistics (research staff/translator unavailable, patient unavailable due to multiple operating room visits, site unable to place IVCF). As the study progressed over 2 years, trauma attendings, residents, and physician extenders became more familiar with the FIT study, which led to timely notification of the research staff of eligibility status by the primary trauma service. To enhance this collaboration, we advertised the FIT study with posters on the trauma units, as well as laminated pocket cards detailing inclusion/exclusion criteria and research staff contact information. We also regularly attended trauma service meetings to reintroduce the FIT study to new residents rotating on the service. We faced several logistic barriers to enrolling patients.
For example, we had difficulty obtaining baseline CUS or informed consent within 96
hours of admission in patients with severe injuries who returned to the operating room multiple times within the first few days of hospitalization. Also, since we did not initially have a dedicated study coordinator, all eligible patients who were admitted to the trauma service over a weekend were not enrolled.
Exclusion and inclusion criteria may have contributed to our low recruitment rates. We excluded patients if they were ineligible for pharmacologic prophylaxis during their entire hospitalization. The clinical question that was to be addressed was whether consents. This key step of obtaining informed consent by one person led to a 65% increase in enrollment rates as well as improved patient/physician compliance with the study protocol. In addition, we instituted an informed consent documentation form to help streamline the informed consent process. This form served as a reminder checklist to document: 1) eligibility requirements, 2) the opportunity given to the patient and family to discuss the study and ask questions, 3) copies of informed consent placed in medical records and given to the patient, and 4) primary and secondary contact information of patient and next-of-kin. In addition, the informed consent documentation form served as a standardized script to explain the study and answer questions most commonly asked by the patient and family.
Follow-up at 1-month post-discharge was significantly better than follow-up after 6 months. If a patient was not scheduled for a clinic appointment as per standard of practice for their injuries the research coordinator conducted follow-up over the phone.
The sole reason for lack of follow-up with patients was inability to contact patients after discharge because of inaccurate contact information in the hospital records. We therefore introduced a contact information sheet as part of the informed consent process. This included the patient's and legal representative's contact phone number and address. At 3 months no patients had their IVCF removed. At 6 months only 2 of the 10 patients eligible for removal had successful retrieval. Of those that did not have retrieval, only 20% were deemed to be at continued risk for VTE justifying non-retrieval of IVCF. Of the remainder who did not have the IVCF removed, 20% were lost to followup with the vascular surgery service. This is consistent with prior reports in the literature of retrieval rates of 20%. 35 Reasons for lack of follow-up to remove filters and methods to improve retrieval rates needs to be addressed prospectively given the recent attention to complications of IVCFs reported in the literature. 24, [36] [37] On August 8, 2010, the FDA issued a safety alert recommending that clinicians responsible for the ongoing care of patients with retrievable IVCFs consider removing the filter as soon as protection from PE is no longer needed. 27 Therefore, improved retrieval rates of IVCFs is mandatory and methods for increasing retrieval rates should be explored.
Despite recent reports of filter complications 24, [36] [37] , placement of pIVCFs may be appropriate when anticoagulation may be contraindicated in the short-term. When removed in a timely fashion, retrievable filters may avoid the long-term complications associated with permanent IVCFs. However, the efficacy of pIVCFs beyond appropriate pharmacologic prophylaxis remains to be elucidated.
We conducted this pilot study feasibility to determine the feasibility of conducting a future large multicenter RCCT evaluating the efficacy of pIVCFs in high-risk trauma.
Our results will help inform the design of a future large trial. We conclude that by addressing the multifaceted issues in recruitment, protocol adherence, and follow-up we faced during this pilot study a multicenter RCCT is feasible. Several key considerations emerge from the results of this study that should be addressed in the protocol of a future large trial. First, since the quality endpoints for our feasibility objectives were met (e.g., enrollment within 96 hours of admission), shorter acceptable time frames for quality endpoints can likely be implemented to prevent exclusion of patients that develop VTE during the first few days of hospitalization. During the first 2 years of this study our institution did not have an electronic medical record system. For recruitment we relied on manual screening of the daily trauma census as well as timely notification of a potential candidate by the primary trauma service. A future trial can maximize recruitment rates by utilizing a computerized alert system that automatically and accurately identifies potential study subjects, thereby improving efficiency of enrollment.
This electronic tool is especially important in time sensitive trials in trauma patients. In addition, this computerized method would effectively reduce the screening burden while minimizing error associated with recruitment by research staff. 
